1H-MRS lipid signal modulation and morphological and ultrastructural changes related to tumor cell proliferation

Magnetic Resonance in Medicine

Volumn 42, Issue 2, 1999, Pages 248-257

  Rosi, Antonella ^a   Luciani, Anna Maria ^a   Matarrese, Paola ^a   Arancia, Giuseppe ^a   Viti, Vincenza ^a   Guidoni, Laura ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

1H MRS; Cell morphology; Ionidamine; Mobile lipids; Tumor cells

Indexed keywords

CELL MEMBRANES; CELL PROLIFERATION; LANTHANUM COMPOUNDS; LIPIDS; METABOLITES; MORPHOLOGY; SCANNING ELECTRON MICROSCOPY; TUMORS;

CELL MORPHOLOGY; CELL-CYCLE PROGRESSION; IONIDAMINE; MORPHOLOGICAL CHANGES; STRUCTURAL MODIFICATIONS; TUMOR CELLS; ULTRASTRUCTURAL CHANGES; ^1H-MRS;

CYTOLOGY;

LIPID; LONIDAMINE; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; FREEZE FRACTURE; HUMAN; HUMAN CELL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; TUMOR CELL; DRUG EFFECT; HELA CELL; LIPID METABOLISM; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; FREEZE FRACTURING; HELA CELLS; HUMANS; INDAZOLES; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING;

EID: 0032587862     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2594(199908)42:2<248::AID-MRM6>3.0.CO;2-I     Document Type: Article

References (36)

1. Mountford CE, Wright LC, Holmes KT, Mackinnon WB, Gregory P, Fox RM. High resolution proton NMR analysis of metastatic cancer cells. Science 1984;226;1415-1418.
2. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE. Cell-surface fucosylation and magnetic resonance spectroscopy characterization of human malignant colorectal cells. Biochemistry 1992;31:11095-11105.
3. Luciani AM, Rosi A, Maggiorella MT, Federico F, Sulli N, Verani P, Rossi GB, Viti V, Guidoni L. Interaction of HIV-1 with susceptible lymphoblastoid cells. FEBS Lett 1991;285:11-16.
4. 1H NMR study. Physiol Chem Phys Med NMR 1992;24:89-96.
5. Holmes KT, Williams PG, Bloom M, Dyne M, Mountford CE, King N, Karaman M, Nihnam B, Blanden R. Magnetic resonance study of lymphocytes stimulated with concanavalin A. Magn Reson Med Biol 1988;1:75-81.
6. Dingley AJ, King GF, King NJC. An NMR investigation of the changes in plasma membrane triglyceride and phospholipid precursors during the activation of T-lymphocytes. Biochemistry 1992;31:9098-9106.
7. 1H MR spectra of neutrophils. Magn Reson Med 1994;31:212-217.
8. 1H-MRS of primary human and murine cells of the myeloid lineage. ImmunoMethods 1994;4:188-198.
9. 1H MR spectrum in murine T cells and B cells occurs in G1 phase of the cell cycle. Magn Reson Med 1990;16:1-8.
10. 1H-MRS visible neutral lipids in activated T lymphocytes: Relationship to phosphatidylcholine cycling. Biochem Biophys Acta 1996;1303:215-221.
11. Delikatny EJ, Roman SK, Hancock R, Jeitner TM, Lander CM, Rideout DC, Mountford CE. Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int J Cancer 1996;67:72-79.
12. Russel P, Lean CL, Delbridge L, May GL, Dowd S, Mountford CE. Proton magnetic resonance and human thyroid neoplasia I: Discrimination between benign and malignant neoplasms. Am J Med 1994;96:383-388.
13. 1H-MRS of high grade astrocytomas: Mobile lipid accumulation in necrotic tissue. NMR Biomed 1994;7:140-155.
14. 1H-MRS in vivo in glial tumors experience of the Siemens cooperative clinical trial. Anticancer Res 1996;16:1485-1490.
15. Gotsis ED, Fountas K, Kapsalaki E, Toulas P, Peristeris G, Papadakis N. In vivo MR spectroscopy: The diagnostic possibilities of lipid resonances in brain tumors. Anticancer Res 1996;16:1565-1568.
16. Mountford CE, Wright LC. Organization of lipids in the plasma membranes of malignant and stimulated cells: A new model. Trends Biochem Sci 1988;13:172-177.
17. 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmatic lipid droplets. Magn Reson Med 1993;29:546-550.
18. Delikatny EJ, Lander CM, Jeitner TM, Hancock R, Mountford CE. Modulation of MR-visible mobile lipid levels by cell culture conditions and correlations with chemotactic response. Int J Cancer 1996;65:238-245.
19. Le Moyec L, Tatoud R, Eugene M, Gauville C, Primot I, Charlemagne D, Calvo F. Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer lines. Br J Cancer 1992;66:623-628.
20. 1H NMR and light microscopy: correlation with activation. In: Proceedings of the ISMRM, 5th Scientific Meeting, Vancouver, 1997. p 549.
21. 1H MR spectroscopy evidences different patterns of lipid metabolites in both radiation- and chemically-transformed cells with respect to the parenteral C3H mouse embryo fibroblast cell line. Phys Med 1997;13(Suppl. 1):287-290.
22. nd Scientific Meeting, San Francisco, 1994. p 1368.
23. Casu M, Anderson GJ, Choi G, Gibbons WA. NMR lipid profiles of cells, tissues and body fluids, I-1D and 2D proton NMR of lipids from rat liver. Magn Reson Chem 1991;29:594-602.
24. Guidoni L, Bella J, Luciani AM, Rosi A, Viti V. MRS studies on lipid and perchloric acid extracts from HeLa cells upon changes in progression though cell cycle. In: Proceedings of ISMRM, 6th Scientific Meeting, Sydney, 1998. p 1683.
25. Gelfant S. A new concept of tissue and tumor cell proliferation. Cancer Res 1977;37:3845-3862.
26. Bhakoo KK, Willims SR, Florian C, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996;56:4630-4635.
27. Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem 1994;269:3858-3867.
28. Smith TAD, Bush C, Jameson C, Titley JC, Leach MO, Wilman DEV, McCready VR. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed 1993;6:318-323.
29. Smith TAD, Eccles S, Box G, Titley JC, Leach MO, McCready VR. Phosphocholine and choline content of rat sarcoma cells grown in the presence and in the absence of serum. Anticancer Res 1996;16:1389-1392.
30. 31P-NMR. Biochem Biophys Acta 1992;1135:27-34.
31. 1H NMR spectroscopy. J Acquir Immune Defic Syndr 1991;4:1073-1081.
32. Malorni W, Meschini S, Matarrese P, Arancia G. The cytoskeleton as a subcellular target of the antineoplastic drug Lonidamine. Anticancer Res 1992;12:2037-2046.
33. Matarrese P, Meschini S, Arancia P, Malorni W. The mode of action of the antitumor agent Lonidamine involves calcium-associated actin filament rounding. Oncol Rep 1994;1:387-393.
34. Floridi A, Lehninger A. Action of the antitumor and antispermatogenic agent lonidamine on the electron transport in Ehrlich ascites tumor cells. Arch Biochem Biophys 1983;226:73-83.
35. Malorni W, Arancia G, De Martino C, Nista A, Accinni L, Masella R, Cantafora A. On the mechanism of action of Lonidamine: a study on human erythrocyte membrane. Exp Mol Pathol 1988;49:361-372.
36. De Martino C, Malorni W, Accinni L, Rosati F, Nista A, Formisano G, Silvestrini B, Arancia G. Cell membrane changes induced by Lonidamine in human erythrocytes, lymphocytes and Ehrlich ascites tumor cells. Exp Mol Pathol 1987;46:15-30.